Programmed death-1 ligand 2 (PD-L2) expression extends beyond macrophages/dendritic cells to B-1 B cells, a distinct B-cell lineage that is responsible for natural immunoglobulin and which is repertoire skewed toward autoreactive specificities. PD-L2 expression is constitutive in B-1 cells, whereas it is inducible in other cell types, suggesting that PD-L2 is regulated differently in the former versus the latter, and this proved to be the case, both in transcription and promotion. B-1 cells express a PD-L2 transcript that lacks exon 1, in contrast to macrophages/dendritic cells for which exon1 is included, reflecting a unique start site upstream of exon 2. PD-L2 transcription in B-1 cells is regulated by a novel intronic promoter located between exons 1 and 2. This intronic promoter binds Octamer binding protein 1 (Oct1) and Oct2, and although these transcription factors are present in all B cells, Oct2 binding is found in vivo only in B-1 cells and not PD-L2-negative B-2 cells. Moreover, the proximal promoter upstream of exon 1 that is active in macrophages is inactive in B-1 cells. Thus, PD-L2 expression is regulated by two different promoters that function in a lineage-specific manner, with the B-1-specific promoter being constitutively active as a result of Oct1 and Oct2 binding.
Introduction
Programmed death 1 (PD-1, CD279) is a 50 to 55-kDa type-I transmembrane protein originally identified in apoptotic T cells that shares homologous sequence with CTLA4 and CD28 and is inducibly expressed following T-cell antigen receptor and B-cell antigen receptor activation. 1, 2 Despite its name, PD-1 appears to have little to do with cell death. Rather, like CTLA4, PD-1 negatively influences lymphocyte activation and in so doing acts to enhance tolerance. 3 This is most clearly evidenced by the phenotype of PD-1-deficient animals: these animals are afflicted with generalized lupus-like autoimmunity complicated by glomerulonephritis or by autoimmune dilated cardiomyopathy associated with troponin-specific autoantibodies, depending on background strain. [4] [5] [6] The general theme that PD-1 downmodulates lymphocyte activity is supported by numerous in vitro and in vivo experiments, including demonstrations of enhanced B-and T-cell stimulation, and more effective antiviral responses, in PD-1-deficient, as compared with normal, animals. 4, 7, 8 Two ligands for PD-1 have been identified, PD-1 ligand 1 (PD-L1) (B7-H1, CD274) and PD-L2 (B7-DC, CD273), both of which are type-I transmembrane proteins. [9] [10] [11] [12] PD-L1 is constitutively and broadly distributed on lymphoid and non-lymphoid cells, encompassing multiple organ systems. The combination of wide tissue expression of PD-L1 plus antigen receptor-induced upregulation of lymphocyte PD-1 has led to the proposal that the PD-L1/PD-1 system functions as a 'fail-safe' mechanism to modulate aberrant autoreactivity. In contrast to PD-L1, PD-L2 expression is much more tightly restricted and has traditionally been considered a characteristic only of activated macrophages and dendritic cells (with perhaps small amounts on thymic stroma and cultured mast cells and, in humans but not in mice, on vascular endothelial cells). 3, [11] [12] [13] [14] [15] [16] Aside from differences in tissue distribution, there is evidence that PD-L2 and PD-L1 differentially affect immune responses and disease processes. For example, antibody blockade or knockout of PD-L1 exacerbated experimental autoimmune encephalitis and accelerated heart, cornea and skin graft rejection, whereas interference with PD-L2 had no effect. [17] [18] [19] [20] [21] Conversely, PD-L2 expression on J558 tumor cells provoked a more vigorous immune response and led to more rapid tumor rejection than did PD-L1 expression, which was instead associated with tumor evasion of host immunity; along the same lines, infection with Leishmania mexicana was exacerbated by the loss of PD-L2 in comparison with wild-type hosts, whereas loss of PD-L1 was associated with host resistance. [22] [23] [24] In addition, PD-L2, but not PD-L1, has been shown to mediate retrograde signaling, leading in dendritic cells to PI-3K-dependent activation of nuclear factor-kB with attendant FLIP-associated apoptosis resistance, TREM-2 mediated antigen uptake, activation of cytokine and chemokine genes and enhanced T-cell stimulation. [25] [26] [27] [28] These results and others 29 add a unique dimension to PD-L2 expression, strongly suggesting that PD-L2 may act as a receptor, signaling for changes in PD-L2-expressing cells, as well as serving as a ligand to affect target cells. Of note, a specific PD-L2 polymorphism (47 103 C/T) has been identified in association with systemic lupus erythematosus, whereas no association was found between systemic lupus erythematosus and any PD-L1 polymorphism, 30 suggesting a correlation between PD-L2 and human autoimmune disease.
Recently, PD-L2 expression was found to extend beyond macrophages and dendritic cells to the B-cell lineage. 31 In particular, PD-L2 expression was shown to characterize a subset of B-1 B cells, whereas B-2 cells are devoid of PD-L2 and cannot be induced to express this surface antigen.
31,32 B-1 cells are a distinct B-cell lineage whose members are responsible for the production of natural immunoglobulin (Ig), which is a necessary effector for successful antimicrobial defense. [33] [34] [35] [36] [37] [38] [39] Moreover, B-1 cell natural Ig is often autoreactive and thus B-1 cells may play a role in autoimmune dyscrasias.
The subpopulation of B-1 cells marked by expression of PD-L2 differs from PD-L2 À B-1 cells in several important ways. The repertoire skewing toward PtCbinding VH11 and VH12 that typifies B-1 cells is much more highly expressed in PD-L2 þ B-1 cells; 31 the Ig crossreactivity with self-antigen that characterizes B-1 cells is much more evident in PD-L2 þ B-1 cells; 40 and the especially efficient antigen presentation that distinguishes B-1 cells is enhanced in PD-L2 þ B-1 cells. 40 These features specifically implicate the PD-L2 þ population of B-1 cells in the origin or perpetuation of autoimmune diseases that contain a strong autoantibody component.
PD-L2 expression on mature B-1 cells is strictly constitutive, and can be neither further upregulated on PD-L2 þ B-1 cells, nor induced on PD-L2 À B-1 cells. 31 This contrasts with other cells, specifically macrophages and dendritic cells, where PD-L2 expression is only apparent after induction by an appropriate stimulus. The contrasting nature of constitutive PD-L2 expression on B-1 cells versus inducible PD-L2 expression on macrophages/dendritic cells strongly suggests that the nature of PD-L2 regulation is different in the former as opposed to the latter, either in terms of the transcript produced or the nature of transactivation. The functional distinctions associated with PD-L2 expression by B-1 cells further raise the possibility that PD-L2 produced in B cells is not the same as that produced in other cell types. To address these issues, we undertook to elucidate the nature and regulation of PD-L2 expression in B-1 cells. We found that B-1 cells express a unique PD-L2 transcript that is regulated in a unique manner by a novel, intronic promoter.
Results

PD-L2 transcripts differ between unstimulated B-1 cells and IL-4-stimulated macrophages in terms of exon composition
We suspected that the Pd-l2 gene is expressed differently in B-1 B cells than in macrophages or dendritic cells, as it is constitutive in the former and inducible in the latter. The murine Pd-l2 locus encompasses six exons ( Figure 1 ) with an ATG start codon in exon 2 and a stop codon in exon 5 ( Figure 1 ). To examine PD-L2 exon usage in B-1 cells, we analyzed mRNA expression by real-time PCR using inter-and intra-exon primer sets (Supplementary  Table) . Primary macrophages stimulated by interleukin-4 (IL-4) to upregulate PD-L2 expressed all six PD-L2 exons, in accordance with the NCBI database (Table 1) . In direct contrast, we found that unstimulated primary B-1 cells, and B-1 cell lines, that are PD-L2 positive failed to express exon 1. Because the ATG start codon for PD-L2 is located in exon 2 (Figure 1 ), PD-L2 þ B-1 cells would be expected to display the same PD-L2 protein as macrophages, and indeed B-1 cell and macrophage PD-L2 is recognized by the same specific monoclonal anti-PD-L2 antibody.
31,32 Interestingly, we found that primary splenic B-2 cells expressed exons 5 and 6 (at a level 20-40% less than that of B-1 cells), which, however, should not yield any PD-L2 product because of the presence of a stop codon in exon 5, and indeed, neither naïve nor stimulated B-2 cells expressed immunoreactive PD-L2. 31, 32 These data suggest that constitutive PD-L2 gene expression in unstimulated B-1 cells might be regulated Table 1 . IL-4, interleukin-4; PD-L2, programmed death-1 ligand 2.
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H Kaku and TL Rothstein in a manner different from inducible PD-L2 in stimulated macrophages.
PD-L2 transcripts differ between unstimulated B-1 cells and IL-4-stimulated macrophages in terms of start site The results above regarding PD-L2 exon usage suggested that the transcription start site in B-1 cells might differ from that in macrophages and could be located in the region around the junction of intron 1 and exon 2. To address this issue, we performed further mRNA expression assays using intron 1 and exon 3 primer sets (Supplementary Table) to determine whether B-1 cells express the extra region upstream of exon 2. We found that B-1 cells, but not IL-4-stimulated macrophages, expressed sequence À82 from exon 2, but neither sequence À198 nor À310 from exon 2 ( Table 2 ). These data suggest that the transcription start site in B-1 cells lies in the region À198 to À89 from exon 2. To identify the exact start site in B-1 cells, we performed rapid amplification of 5 0 -complementary DNA (cDNA) ends (5 0 RACE) using total RNA from PD-L2 þ B-1 cells in comparison with total RNA from IL-4-stimulated macrophages. After amplifying 5 0 PD-L2 cDNA by nested PCR, we evaluated the PCR products on 2% agarose gels and noted that each cell type yielded a single band (Figure 2a) . Further, the band derived from B-1 cells appeared a bit smaller than that derived from macrophages, suggesting that a single transcription start site differs between B-1 cells and macrophages in a cell typespecific manner. These bands were then TA-cloned and their sequences analyzed, revealing that the transcription start site in PD-L2 þ B-1 cells was À146 bp from exon 2 (all of the three bacteria-derived clones), while that in IL-4-stimulated macrophages was þ 34 bp from exon 1 (all of the three bacteria-derived clones), in comparison with the known dendritic cell cDNA sequence according to the NCBI database (NM_021396) (Figure 2b) . The difference in the transcription start sites for PD-L2 expression between B-1 cells and IL-4-stimulated macrophages raises the possibility that the PD-L2 gene may be regulated differently in these cell types.
A proximal, upstream region promotes PD-L2 expression in macrophages but not in B-1 cells To determine the genomic region responsible for PD-L2 gene expression in murine B-1 cells, we first analyzed the proximal promoter sequence recorded in the NCBI database (NM_021396), using PromoterInspector (http://www.genomatix.de/index.html), which predicts promoter or enhancer regions using database-derived patterns. This algorithm predicted that the PD-L2 promoter is located within the region À5279 to À5040 in relation to exon 1. With this in mind, we cloned the 
Abbreviations: gDNA, genomic DNA; IL-4, interleukin-4; PD-L2, programmed death-1 ligand 2.
a Genomic DNA was purified from BALB/c tail and used as a control. 0 PD-L2 cDNA by nested PCR (a) PCR products were separated by electrophoresis on 2% agarose gels and visualized with 2 mg ml À1 ethidium bromide and (b) PCR products were TA-cloned into the pGEM-T vector, after which the insert was verified by sequencing and the transcription start site was determined. cDNA, complementary DNA; IL-4, interleukin-4; PD-L2, programmed death-1 ligand 2; 5 0 RACE, rapid amplification of 5 0 cDNA ends.
H Kaku and TL Rothstein region À5574 to þ 5 from exon 1 into the pGL4.10 firefly luciferase reporter vector, and examined luciferase expression following reporter gene transfection into B-cell and macrophage cell lines, which were used as models for primary cells because of their superior transfection efficiency. We transfected two B-1 cell lines that constitutively express PD-L2 (BRD2 and BCL1), and one macrophage cell line that constitutively expresses PD-L2 (RAW264.7). We found that RAW264.7 cells transfected with the À5574/ þ 5 reporter vector expressed approximately ninefold more luciferase than did RAW264.7 cells transfected with empty reporter vector ( Figure 3a) . In marked contrast, the upstream promoter region was not active in B-1 cell lines inasmuch as the level of luciferase activity produced by transfection of the À5574/ þ 5 reporter vector was the same as that produced by transfection of the empty reporter vector ( Figure 3a ). Because PD-L2 expression was induced in macrophages and dendritic cells by cytokines including IL-4, 32 we stimulated B-1 cell lines with IL-4 or peritoneal cavity fluid, which contains IL-6 and IL-10, and which surrounds primary B-1 cells in situ. In spite of stimulation, B-1 cell lines failed to enhance À5574/ þ 5 reporter activity (data not shown). These results indicate that the PD-L2 gene responds to a different promoter in B-1 cells as opposed to macrophages, where a proximal, upstream region regulates gene expression.
An intronic region promotes PD-L2 expression in B-1 cells
In view of the unique exon usage for PD-L2 transcripts in B-1 cells, and the novel start site for B-1 cell PD-L2 transcripts within the intronic region upstream of exon 2, we speculated that PD-L2 expression may be controlled in B cells by an intronic promoter. To test this, we cloned the intron 1 genomic region (À3032 to þ 5 from exon 2) into the pGL4.10 firefly luciferase reporter vector (even though PromoterInspector predicted no promoter in this region), and examined luciferase expression following reporter gene transfection into B-cell lines. In contrast to the negative results obtained with the proximal promoter region, we found that the intron 1 region promoted transcription of the luciferase reporter gene in both B-1 cell lines, in the absence of stimulation ( Figure 3b ). Thus, the promoter for PD-L2 expression in B-1 cells is likely Figure 3 A proximal, upstream region promotes PD-L2 expression in macrophages but not B-1 cells, whereas an intronic region promotes PD-L2 expression in B-1 cells. (a) BCL1, BRD2 and RAW264.7 cells were transiently transfected with an empty firefly luciferase construct, or with firefly luciferase reporter constructs containing genomic sequence from À5574 to þ 5 in relation to exon 1, along with, in each case, a thymidine kinase promoter-dependent Renilla luciferase expression vector. (b) BCL1 and BRD2 cells were transiently transfected with an empty firefly luciferase construct, or with firefly luciferase reporter constructs containing genomic sequence from À3032 to þ 5 in relation to exon 2. For both panels a and b, cell lysates were prepared and luciferase activity was measured in relation to the Renilla luciferase control. Results are reported as multiples of the activity present with empty vector. For each of panels a and b, mean values for three independent experiments are shown, along with lines corresponding to the standard errors of the means. PD-L2, programmed death-1 ligand 2.
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H Kaku and TL Rothstein located in the intron 1 region between À3032 to þ 5 in relation to exon 2, and not in the region proximal to and upstream of exon 1, as is the case for macrophages. Presumably this region contains sites for cell type-specific enhancing elements that promote PD-L2 expression.
A small sequence within the intronic region proximal to exon 2 promotes PD-L2 expression in B-1 cells In order to identify more precisely within the À3032 to þ 5 sequence (in relation to exon 2) the active region for promotion of B-1 cell PD-L2 expression, we prepared and tested a series of mutant reporter constructs using the pGL4.10 vector. We transfected these deletion mutant reporter constructs (À1465 to þ 5, À911 to þ 5, À708 to þ 5 and À404 to þ 5 from exon 2) into BRD2 B-1 cells and analyzed reporter activity. We found that all of the mutant intronic promoter constructs produced similar levels of luciferase activity (Figure 4a ). These results indicate that the promoter region controlling PD-L2 transcription in B-1 cells is located within the intronic sequence À404 to þ 5 in relation to exon 2.
In order to further narrow the location of the intronic sequence that regulates PD-L2 expression in B-1 cells, we prepared and tested additional mutant reporter constructs. We first focused on the 3 0 edge of the À404/ þ 5 region that is downstream of the transcription start site identified in primary B-1 cells (À146 in relation to exon 2), by comparing the region À404 to À136 with the positive control region À404 to þ 5, in relation to exon 2, after transfection into BRD2 cells. We found that luciferase reporter gene activity was as active, or more active, in the former as compared with the latter (Figure 4b ). These results indicate that the sequence À136 to þ 5 from exon 2 is not required for PD-L2 expression in B-1 cells and draw attention to the region À404 to À136. We then evaluated this sequence in more detail, focusing on the 5 0 edge by comparing the region À313 to À136 and À240 to À136 with the positive control region À404 to À136, in relation to exon 2, after transfection into BRD2 cells. We found that luciferase reporter gene activity was at least as active in the two test constructs as compared to the positive control ( Figure 4c ). In fact, the sequence À240 to À136 was more active than either À404 to À136 or À313 to À136, raising the possibility that a negative regulatory site lies within the region from À313 to À241. These results indicate that positive elements responsible for PD-L2 expression in B-1 cells are contained within the relatively narrow (94 bp) range of intronic sequence downstream of À240 in relation to exon 2, as confirmed by mutational studies summarized below in Figure 6 .
Oct1 and Oct2 transcription factors bind to the PD-L2 intronic promoter To identify factors responsible for promoting PD-L2 expression that bind within the 94 bp intronic segment, we carried out electrophoretic mobility shift assays (EMSA) on B-cell nuclear extracts, using the region À240 to À147 as labeled probe. We tested extracts obtained from primary B-1 and B-2 cells as well as extracts obtained from B-1 (BCL2, BRD2) and B-2 (A20) cell lines. Four nucleoprotein complexes were detected, labeled A, B, C and D (Figure 5a ). Two complexes (A and B) were shared by all the samples (Figure 5a ). In contrast, complex C was most readily apparent in BRD2 extracts and complex D was most readily apparent in A20 extracts (Figure 5a ). In contrast to the marked bands, which were always observed as noted above, the faint bands located in between complexes C and D were not reproducible (data not shown). Thus, we detected no nucleoprotein complexes that consistently distinguished primary B-1 from primary B-2 cells, even though more than half of primary B-1 cells express PD-L2, whereas no B-2 cells do so (Figure 5a ).
We focused further on the A and B nucleoprotein complexes because these were the only bands that were abundantly and consistently present in nuclear extracts from primary B cells. To more fully define the DNAbinding sites participating in these complexes, we performed 'cold' competition analysis using subsections of the À240 to À147 sequence. Thus, to EMSA binding reactions using labeled À240 to À147 probe, we added unlabeled ('cold') DNA consisting of À240 to À213, À212 to À191, À190 to À169, À168 to À147, and, as a positive control, the (unlabeled) probe sequence of À240 to À147, all in relation to exon 2. We found, as expected, that addition of unlabeled probe sequence (À240 to À147) completely competed the formation of both the A and B nucleoprotein complexes (Figure 5b) . None of the other DNA competitors were as effective; however, two of the sequences produced partial inhibition of both the A and B nucleoprotein complexes: À240 to À213 and À190 to À169 from exon 2 ( Figure 5b ). These results raised the possibility that important promoter-binding sites might be located in these two regions. We then analyzed these sequences via the Transfac Database, and found that both regions contained Octamer binding sites, although the sites in these two regions are both non-canonical and are characterized by an affinity for Octamer protein that is 41 and it is likely that the anti-Oct1 antiserum does not bind with equal efficiency to all isoforms. Regardless, these results indicate that the A nucleoprotein complex contains Oct1, and that the B nucleoprotein complex contains Oct2.
Octamer binding sites are responsible for PD-L2 expression in B-1 cells
To determine the role of the A and B Octamer binding sites in promoting B-1 cell expression of PD-L2, we prepared and tested luciferase reporter constructs encompassing the sequence À240 to À136, in relation to exon 2, in native form or encompassing mutation of one or both of the A and B Octamer binding motifs. These reporter constructs were transfected into BRD2 B-1 cells and luciferase activity was evaluated. We found that mutation of a single site, either A or B, substantially blocked luciferase activity and that mutation of both sites virtually eliminated expression of the luciferase reporter gene (Figure 6a) . These results indicate that Octamer binding sites within the intronic sequence À240 to À136 from exon 2, that bind Oct1 and Oct2, are together responsible for PD-L2 gene expression in B-1 cells.
Oct2 binds to the PD-L2 intronic promoter in vivo To more fully evaluate the physiological role of Octamer binding sites within the intronic promoter sequence in primary B cells, we performed chromatin immunoprecipitation (ChIP) assays using anti-Oct2 antibody, as described under Materials and methods. We found that Oct2 constitutively bound to the intronic promoter in isolated peritoneal PD-L2 þ primary B-1 cells, but not in primary splenic B-2 cells (that do not express PD-L2 under any circumstances); further, we found that Oct2 
OA downregulates PD-L2 expression in primary B-1 cells
To further examine the role of Oct2 in directing primary B-1 cell PD-L2 surface expression, we evaluated the effect of okadaic acid (OA), a serine and threonine phosphatase inhibitor that promotes phosphorylation of Oct2. 42 This results in an observable shift in the molecular size of Oct2 and a decrease in binding affinity of Oct2 for noncanonical Octamer motifs. 42 We treated primary B-1 and primary B-2 cells with OA and carried out western blotting using anti-Oct2 antibody (Figure 7a ). OA treatment produced substantial increase in the apparent molecular size of Oct2 consistent with phosphorylation ( Figure 7a ). The loss of Oct2 at later time points after OA treatment that is apparent in Figure 7a has been noted elsewhere and is presumably due to targeting of phosphorylated Oct2 for degradation; 42 importantly, there was no decrease in viability during the 9-h treatment with OA. We then analyzed PD-L2 surface expression in OA-treated cells by flow cytometry. OA treatment of primary B-1 cells produced downregulation of PD-L2 surface expression (Figure 7b ). These results further suggest that Oct2 is responsible for PD-L2 expression in B-1 cell types.
Discussion
We previously reported that PD-L2 is constitutively expressed by a subpopulation of B-1 cells, whereas PD-L2 expression by other cell types such as macrophages and dendritic cells is not constitutive but rather cytokine-induced in nature. Along with the distinctive functional attributes of PD-L2 þ B-1 cells, this raised the possibility that PD-L2 is regulated differently in B cells as opposed to macrophages and dendritic cells. In pursuing this issue, we found that B-1 cell PD-L2 is generated via a novel transcript that is regulated by a novel promoter.
Programmed death-1 ligand 2 gene expression in B-1 cells differs from that in macrophages and dendritic cells in terms of exon usage, inasmuch as exon 1 is omitted from the former but is a constituent of the latter. This difference is unlikely to alter the structure of the PD-L2 protein product, because the translation start site for PD-L2 lies in exon 2, which is a component of PD-L2 transcripts even in the absence of exon 1. Consistent with this, Ig reagents that recognize macrophage and dendritic cell PD-L2 similarly recognize B-1 cell PD-L2. 31, 32 Still, this transcriptional difference suggests an underlying difference in promoter structure/function, particularly in view of the fact that the region À146 to À1 in relation to exon 2 is expressed in B-1 cells, ruling out an alternative splice mechanism in the generation of PD-L2 transcripts lacking exon 1. Further study demonstrated that the proximal promoter that directs PD-L2 expression in macrophages is inactive in B-1 cell lines, wherein, instead, PD-L2 expression is controlled by a newly identified, novel intronic promoter upstream of exon 2.
It has been reported that inducible expression of PD-L2 in macrophages and dendritic cells requires STAT family molecules which are activated by cytokines or nuclear factor-kB. 32 Conversely, B-1 cells that express PD-L2 do so constitutively, in the absence of stimulation, which suggests that transcription factors required for B-1 cell PD-L2 expression are continually expressed and active in B-1 cells. Deletional analysis of the PD-L2 intronic promoter identified a relatively small active region which was shown to contain two Octamer binding sites necessary for gene expression. This intronic promoter region specifically binds Oct1 and Oct2, two transcription factors known to be expressed in B cells. 43 Although the proximal promoter that was active in macrophages was inactive in B-1 cells, the converse is not true, and the intronic promoter that was active in B-1 A key issue concerns the use of distinct genetic mechanisms to produce the same protein. The functional consequences of lineage-specific promoter activity for PD-L2 are clear, in terms of constitutive versus inducible expression of this protein by different cell types resulting from reliance on intronic versus upstream sequences, respectively. As such, the present results provide a new dimension to understanding B-1 cell behavior and the lineage-specific generation of a key PD-1 ligand.
Materials and methods
Mice
Male BALB/cByJ mice at 8-14 weeks of age were obtained from The Jackson Laboratory (Bar Harbor, ME, USA). Mice were housed at least 1 week before experimentation. Mice were cared for and handled in accordance with National Institutes of Health and institutional guidelines. 31, 44 Splenic B2 cells were obtained by negative selection of splenocytes with anti-Thy1.2 antibody and rabbit complement, as previously described. 45 Isolated peritoneal B-1a cells and splenic B-2 cells were 495% pure on re-analysis. Macrophages were obtained from peritoneal washouts by adherence to plastic tissue culture dishes, and were then stimulated with IL-4 (10 ng ml À1 ) (R&D Systems, Minneapolis, MN, USA). Primary cells were cultured in Rosewell Park Memorial Institute (RPMI) 1640 medium containing 10% fetal calf serum, 10 mM HEPES, 2 mM L-glutamine, 0.1 mg ml À1 penicillin and streptomycin, and 50 mM 2-ME.
B lymphoma cell lines A20 and BCL1 B-cell lymphomas were obtained from the American Type Culture Collection (Manassas, VA, USA). BRD2 B-1-cell lymphoma was obtained from Dr G Denis (Boston University Medical Center, Boston, MA, USA). RAW264.7 macrophages were kindly provided by Dr K Takahashi (The Feinstein Institute for Medical Research, Manhasset, NY, USA). Cell lines were cultured in RPMI 1640 medium as described above.
Antibodies and reagents Antibody 2.4G2 (anti-mouse FcgR), fluorescein isothiocyanate-conjugated antibody RA3-6B2 (anti-B220), phycoerythrin (PE)-conjugated antibody TY25 (anti-PD-L2) and PE-Cy5-conjugated antibody 53-7.3 (anti-CD5) were obtained from BD Pharmingen (San Diego, CA, USA). Rabbit polyclonal antibodies directed against Oct1 and Oct2 were obtained from Chemicon (Temecula, CA, USA) and Santa Cruz (Santa Cruz, CA, USA), respectively. OA was obtained from EMD Chemical (Gibbstown, NJ, USA) and dissolved in dimethylsulfoxide.
5
0 RACE analysis Total RNA from PD-L2 þ B-1 cells and from macrophages was isolated with Ultraspec RNA Reagent (Biotecx, Houston, TX, USA) for 5 0 RACE using 5 0 -Full RACE Core Set (Takara Bio, Otsu, Japan) according to the manufacturer's instructions, as previously reported. 46 Briefly, the unknown region was amplified by nested PCR (two-step PCR) using LA-Taq (Takara Bio). PCR products were separated by electrophoresis on 2% agarose gels and visualized with ethidium bromide. After checking the band pattern, PCR products were TAcloned into pGEM-T vector (Promega, Madison, WI, USA). The insert was verified by sequencing (Genewiz, South Plainfield, NJ, USA) and the transcription start site was determined. Sequence information for the primers used in 5 0 RACE is shown in the Supplementary Table. ChIP assay Chromatin immunoprecipitation assay was performed with reagents from Upstate Biotechnology (Lake Placid, NY, USA), according to the manufacturer's protocol, as previously described, with slight modification. 47 Briefly, primary B cells (2 Â 10 6 ) were subjected to chromatin cross-linking in 1% formaldehyde for 2 min at 37 1C, and quenched with glycine (125 mM). Cell lysates were sonicated to shear the DNA length to between 200 and 2000 bp; DNA was extracted from a fraction of the lysate for input controls. Precleared lysates were incubated overnight at 4 1C with rabbit anti-Oct2 antibody or with normal rabbit IgG (4 mg each). Cross-linking was reversed and input and immunoprecipitated DNA samples were assayed for the PD-L2 promoter sequence by real-time PCR. The sequences of the primer sets used in the ChIP assays are shown in the Supplementary Table.
Construction of reporter plasmid and transfection
The PD-L2 genomic region was amplified by PCR using LA-Taq. PCR products were cloned into the pGL4.10 luciferase vector (Promega). Mutant reporters were constructed using LA-Taq and QuickChange Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA, USA). The insert was verified by sequencing (Genewiz). Native and mutant firefly luciferase vectors were cotransfected with pRL-TK (Renilla luciferase) vector using the nucleofector kit V (Amaxa, Walkersville, MD, USA) according to the manufacturer's instructions. At 24 h after transfection, luciferase activity in cell lysates was analyzed by the Dual-Luciferase Reporter Assay System (Promega) according to the manufacturer's instructions, using a 20/20n Single Tube Luminometer (Turner Biosystem, Sunnyvale, CA, USA). Relative luciferase activity was calculated as firefly luciferase activity/Renilla luciferase activity and the data shown represent the mean fold induction of two to three experiments. The sequences of the primer sets used in cloning are shown in the Supplementary Table. qPCR mRNA expression analysis Total RNA was extracted from primary PD-L2 þ B-1a cells, PD-L2 À B-1a cells, B-2 cells and macrophages, and from B lymphoma cell lines, using Ultraspec according to the manufacturer's instructions. RNA was reverse transcribed (iScript cDNA synthesis kit; Bio-Rad, Hercules, CA, USA), amplified by real-time PCR and normalized to expression of b2-microglobulin, as previously described. 48 The sequences of the primer sets are shown in the Supplementary Table.
Nuclear protein extraction and EMSA Nuclear extracts were obtained from B cells and analyzed by EMSA as previously described. 49 In brief, B cells (5 Â 10 6 ) were washed with HBSS and disrupted for 10 min on ice using hypotonic lysis buffer (10 mM HEPES, pH 7.9, 10 mM KCl, 1.5 mM MgCl 2 ). Nuclear fractions were collected and suspended for 20 min on ice in extraction buffer (20 mM HEPES, pH 7.9, 420 mM KCl, 1.5 mM MgCl 2 , 20% glycerol). All buffers were supplemented with a protease inhibitor cocktail, phenylmethyl sulfonyl fluoride (0.5 mM), sodium orthovanadate (1 mM) and dithiothreitol (1 mM). Nuclei were pelleted and supernatants were collected as nuclear protein extracts and were stored at -801 C. Protein concentrations were determined by Bradford method (Bio-Rad).
EMSA reaction mixtures (20 ml) contained 2-4 mg of nuclear protein, 2 mg of poly dI:dC (GE Healthcare, Piscataway, NJ, USA) and 4 Â 10 4 c.p.m. per 2 ml of 32 P end-labeled probe. For EMSA competitor assays, 50 Â cold excess competitor was added before adding labeled probe. For EMSA supershift or nucleoprotein complex depletion assay, 2 mg of anti-Oct1, anti-Oct2 and normal rabbit IgG were added to reaction mixtures and incubated at 4 1C for 1 h before adding probe. The sequences of the probes and cold competitors used in EMSA are shown in the Supplementary Table. Reaction mixtures were incubated at room temperature for 30 min and the nucleoprotein complexes were resolved on native 4% polyacrylamide gel in 0.25 Â Tris-borate-EDTA buffer for electrophoretic analysis at 150 V. Gels were dried and subjected to X-ray films.
Flow cytometry
Cell-surface phenotype was analyzed as previously described. 50 In brief, for flow cytometric analysis, cells pretreated with 2.4G2 (5 mg ml À1 ) were stained with fluorescein isothiocyanate-, PE-or PE-Cy5 conjugated monoclonal antibody in staining buffer (phosphate-buffered saline containing 2% fetal calf serum and 0.05% NaN 3 ) on ice for 30 min and washed with staining buffer. Stained cells were analyzed with a FACSCalibur instrument (Becton Dickinson) equipped with CellQuest software. 7-Aminoactinomycin D (2 mg ml À1 ) (BD Pharmingen) was used to exclude dead cells from the analysis. For each sample, at least 1 Â 10 4 cells were collected and analyzed.
